Cytek Biosciences, Inc. (CTKB) Misses Q4 EPS by 2c
Tweet
Share
E-mailGet Alerts CTKB Hot Sheet
Join SI Premium – FREE
Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q4 EPS of $0.02, $0.02 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $164.04 million versus the consensus estimate of $50.22 million.
For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Geospace Technologies (GEOS) Misses Q3 EPS by 75c
- Cytosorbents (CTSO) Misses Q2 EPS by 1c
- Alector Inc. (ALEC) Tops Q2 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
